Litcius/Paper detail

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial

Takashi Kadowaki, Rina Chin, Akichika Ozeki, Takeshi Imaoka, Yoshihiro Ogawa

2022The Lancet Diabetes & Endocrinology124 citationsDOI

Topics & Concepts

MedicineTolerabilityType 2 diabetesAdverse effectClinical endpointRandomized controlled trialDiabetes mellitusInternal medicineIncidence (geometry)EndocrinologyPhysicsOpticsDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial | Litcius